SOX11 is useful in differentiating cyclin D1-positive diffuse large B-cell lymphoma from mantle cell lymphoma

Histopathology

Volumn 61, Issue 4, 2012, Pages 685-693

  Hsiao, Shih Chuan ^a   Cortada, Inmaculada Ribera ^b   Colomo, Luis ^b   Ye, Hongtao ^c   Liu, Hongxiang ^d   Kuo, Szu Yin ^e   Lin, Shu Hui ^e   Chang, Sheng Tsung ^e   Kuo, Ted U ^a   Campo, Elias ^b   Chuang, Shih Sung ^e,f  

^a ST MARTIN DE PORRES HOSPITAL   (Taiwan)

^b UNIVERSITY OF BARCELONA   (Spain)

^c UNIVERSITY COLLEGE LONDON   (United Kingdom)

^d ADDENBROOKE S HOSPITAL   (United Kingdom)

^e Chi Mei Medical Centre   (Taiwan)

^f TAIPEI MEDICAL UNIVERSITY   (Taiwan)

Author keywords

CCND1; Cyclin D1; Diffuse large B cell lymphoma; Double hit lymphoma; Mantle cell lymphoma

Indexed keywords

CYCLIN D1; CYCLOPHOSPHAMIDE; DOXORUBICIN; MYC PROTEIN; PREDNISOLONE; PROTEIN BCL 6; RITUXIMAB; TRANSCRIPTION FACTOR SOX11; VINCRISTINE; CCND1 PROTEIN, HUMAN; SOX11 PROTEIN, HUMAN; TRANSCRIPTION FACTOR SOX; TUMOR MARKER;

ADULT; AGED; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER IMMUNOTHERAPY; CANCER RADIOTHERAPY; CANCER REGRESSION; COHORT ANALYSIS; CONTROLLED STUDY; DIAGNOSTIC ERROR; DIFFERENTIAL DIAGNOSIS; EPSTEIN BARR VIRUS; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; GENE REARRANGEMENT; HUMAN; LARGE CELL LYMPHOMA; MAJOR CLINICAL STUDY; MALE; MANTLE CELL LYMPHOMA; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; RETROSPECTIVE STUDY; TUMOR NECROSIS; BIOSYNTHESIS; IMMUNOHISTOCHEMISTRY; LYMPHOMA, LARGE B-CELL, DIFFUSE; LYMPHOMA, MANTLE-CELL; METABOLISM; MIDDLE AGED; TISSUE MICROARRAY;

HUMAN HERPESVIRUS 4;

ADULT; AGED; BIOMARKERS, TUMOR; CYCLIN D1; DIAGNOSIS, DIFFERENTIAL; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION, FLUORESCENCE; LYMPHOMA, LARGE B-CELL, DIFFUSE; LYMPHOMA, MANTLE-CELL; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; SOXC TRANSCRIPTION FACTORS; TISSUE ARRAY ANALYSIS;

EID: 84871920576     PISSN: 03090167     EISSN: 13652559     Source Type: Journal    
DOI: 10.1111/j.1365-2559.2012.04260.x     Document Type: Article

References (28)

1. Bosch F, Jares P, Campo E et al. PRAD-1/cyclin D1 gene overexpression in chronic lymphoproliferative disorders: a highly specific marker of mantle cell lymphoma. Blood 1994; 84; 2726-2732.
2. de Boer CJ, Kluin-Nelemans JC, Dreef E et al. Involvement of the CCND1 gene in hairy cell leukemia. Ann. Oncol. 1996; 7; 251-256.
3. O'Malley DP, Vance GH, Orazi A. Chronic lymphocytic leukemia/small lymphocytic lymphoma with trisomy 12 and focal cyclin d1 expression: a potential diagnostic pitfall. Arch. Pathol. Lab. Med. 2005; 129; 92-95.
4. Chang ST, Liao YL, Lu CL, Chuang SS, Li CY. Plasmablastic cytomorphologic features in plasma cell neoplasms in immunocompetent patients are significantly associated with EBV. Am. J. Clin. Pathol. 2007; 128; 339-344.
5. Olsen B, Srkalovic G, Law M, McPhail E. Cyclin D1 positive follicular lymphoma. J. Clin. Pathol. 2009; 62; 855-857.
6. Rodriguez-Justo M, Huang Y, Ye H et al. Cyclin D1-positive diffuse large B-cell lymphoma. Histopathology 2008; 52; 900-903.
7. Ehinger M, Linderoth J, Christensson B, Sander B, Cavallin-Stahl E. A subset of CD5- diffuse large B-cell lymphomas expresses nuclear cyclin D1 with aberrations at the CCND1 locus. Am. J. Clin. Pathol. 2008; 129; 630-638.
8. Teruya-Feldstein J, Gopalan A, Moskowitz CH. CD5 negative, cyclin D1-positive diffuse large B-cell lymphoma (DLBCL) presenting as ruptured spleen. Appl. Immunohistochem. Mol. Morphol. 2009; 17; 255-258.
9. Schneider A, Meyer P, DimMaio D, Fu K. Diffuse large B-cell lymphoma with both CD5 and cyclin D1 expression-a case report and review of the literature. J. Hematop. 2010; 3; 145-148.
10. Vela-Chavez T, Adam P, Kremer M et al. Cyclin D1 positive diffuse large B-cell lymphoma is a post-germinal center-type lymphoma without alterations in the CCND1 gene locus. Leuk. Lymphoma 2011; 52; 458-466.
11. Lucioni M, Novara F, Riboni R et al. CD5()) diffuse large B-cell lymphoma with peculiar cyclin D1+ phenotype. Pathologic and molecular characterization of a single case. Hum. Pathol. 2011; 42; 1204-1208.
12. Ek S, Dictor M, Jerkeman M, Jirstrom K, Borrebaeck CA. Nuclear expression of the non B-cell lineage Sox11 transcription factor identifies mantle cell lymphoma. Blood 2008; 111; 800-805.
13. Wang X, Asplund AC, Porwit A et al. The subcellular Sox11 distribution pattern identifies subsets of mantle cell lymphoma: correlation to overall survival. Br. J. Haematol. 2008; 143; 248-252.
14. Mozos A, Royo C, Hartmann E et al. SOX11 expression is highly specific for mantle cell lymphoma and identifies the cyclin D1- negative subtype. Haematologica 2009; 94; 1555-1562.
15. Chuang SS, Ye H, Yang SF et al. Perforation predicts poor prognosis in patients with primary intestinal diffuse large B-cell lymphoma. Histopathology 2008; 53; 432-440.
16. Hans CP, Weisenburger DD, Greiner TC et al. Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. Blood 2004; 103; 275-282.
17. Metcalf RA, Zhao S, Anderson MW et al. Characterization of Dcyclin proteins in hematolymphoid neoplasms: lack of specificity of cyclin-D2 and D3 expression in lymphoma subtypes. Mod. Pathol. 2010; 23; 420-433.
18. Kluin PM, Harris NL, Stein H et al. B-cell lymphoma, unclassifiable, with features intermediate between DLBCL and Burkitt lymphoma. In Swerdlow SH, Campo E, Harris NL et al. eds. WHO classification of tumours of haemtopoietic and lymphoid tissues. Lyon: IARC, 2008; 265-266.
19. Boxer LM, Dang CV. Translocations involving c-myc and c-myc function. Oncogene 2001; 20; 5595-5610.
20. Kramer MH, Hermans J, Wijburg E et al. Clinical relevance of BCL2, BCL6, and MYC rearrangements in diffuse large B-cell lymphoma. Blood 1998; 92; 3152-3162.
21. Winter JN, Weller EA, Horning SJ et al. Prognostic significance of Bcl-6 protein expression in DLBCL treated with CHOP or RCHOP: a prospective correlative study. Blood 2006; 107; 4207-4213.
22. Vitolo U, Gaidano G, Botto B et al. Rearrangements of bcl-6, bcl-2, c-myc and 6q deletion in B-diffuse large-cell lymphoma: clinical relevance in 71 patients. Ann. Oncol. 1998; 9; 55-61.
23. Akasaka T, Akasaka H, Ueda C et al. Molecular and clinical features of non-Burkitt's, diffuse large-cell lymphoma of B-cell type associated with the c-MYC/immunoglobulin heavy-chain fusion gene. J. Clin. Oncol. 2000; 18; 510-518.
24. Kanungo A, Medeiros LJ, Abruzzo LV, Lin P. Lymphoid neoplasms associated with concurrent t(14;18) and 8q24/c- MYC translocation generally have a poor prognosis. Mod. Pathol. 2006; 19; 25-33.
25. Le Gouill S, Talmant P, Touzeau C et al. The clinical presentation and prognosis of diffuse large B-cell lymphoma with t(14;18) and 8q24/c-MYC rearrangement. Haematologica 2007; 92; 1335-1342.
26. Niitsu N, Okamoto M, Miura I, Hirano M. Clinical features and prognosis of de novo diffuse large B-cell lymphoma with t(14;18) and 8q24/c-MYC translocations. Leukemia 2009; 23; 777-783.
27. Snuderl M, Kolman OK, Chen YB et al. B-cell lymphomas with concurrent IGH-BCL2 and MYC rearrangements are aggressive neoplasms with clinical and pathologic features distinct from Burkitt lymphoma and diffuse large B-cell lymphoma. Am. J. Surg. Pathol. 2010; 34; 327-340.
28. Ueda C, Nishikori M, Kitawaki T, Uchiyama T, Ohno H. Coexistent rearrangements of c-MYC, BCL2, and BCL6 genes in a diffuse large B-cell lymphoma. Int. J. Hematol. 2004; 79; 52-54.